Abstract

BackgroundTuberculous infections in patients with hematological disorders and hematopoietic stem cell transplant vary in incidence, complications and response to treatment.Methods and materialsA retrospective study of patients with various benign and malignant hematological disorders and recipients of hematopoietic stem cell transplant who were treated at Riyadh Armed Forces Hospital, Saudi Arabia between January 1991 and December 2002 and who developed tuberculous infections was conducted.ResultsTuberculous infections occurred in eighteen patients with hematological disorders and hematopoietic stem cell transplant. The main associated factors were: reduced immunity due to the primary hematological disorder, age more than 50 years and the administration of cytotoxic chemotherapy, steroids or radiotherapy. These infections frequently involved the lungs and predominantly occurred in males and in patients with chronic myeloproliferative disorders, myelodysplastic syndrome and acute myeloid leukemia. In patients treated with intravenous cytotoxic chemotherapy, tuberculous infections tended to occur earlier and also tended to be more disseminated compared to infections occurring in patients treated with oral chemotherapy. Anti-tuberculous treatment was given to 16 patients and it was successful in 15 of these patients.ConclusionTuberculous infections cause significant morbidity and mortality in patients with various hematological disorders and in recipients of hematopoietic stem cell transplant. The early administration of anti-tuberculous therapy and compliance with drug treatment are associated with successful outcomes while delayed management, drug resistance and the presence of miliary infections are associated with poor prognosis and high mortality rates.

Highlights

  • Tuberculous infections (TIs) are serious and life-threatening complications in patients with malignant hematological disorders and in recipients of hematopoietic stem cell transplant (HSCT) [1,2,3,4,5,6,7]

  • A positive result is indicated by an induration of at least 10 mm in diameter

  • TIs developed in: 4 out of 128 patients with acute myeloid leukemia (AML) treated at our institution; 3 out of 51 patients with chronic myeloid leukemia (CML) (5.9%); 3 out of 41 patients with myelodysplastic syndrome (MDS) (7.3%); 1 out of 25 patients with severe aplastic anemia (SAA) (4%); 1 out of 10 patients with hairy cell leukemia (HCL) (10%); 1 out of 12

Read more

Summary

Introduction

Tuberculous infections (TIs) are serious and life-threatening complications in patients with malignant hematological disorders and in recipients of hematopoietic stem cell transplant (HSCT) [1,2,3,4,5,6,7]. Reactivation of latent tuberculosis (TB) may be induced by the administration of cytotoxic chemotherapy and high dose corticosteroid therapy [1,3,4,8]. The efficacy of anti-TB chemotherapy in patients with hematological malignancies and in recipients of HSCT is well documented [4,9]. Tuberculous infections in patients with hematological disorders and hematopoietic stem cell transplant vary in incidence, complications and response to treatment

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.